Super Alchemy Kind Reborn In City

"All the pages, repeat a story?" Typesetters are full of doubts. This kind of thing has never happened.

"This news is only reported in the first page, other pages are blank."

"Only one report." The typesetters couldn't believe it. This kind of thing, don't say it happened, I've never heard of it.

"Yes."

"It will annoy a lot of users and then unsubscribe from our newspaper." The typesetters advised.

"No. The value of this news will make them have no objection. "

The person in charge of typesetting was stunned for a long time and received the news.

The doctors in the medical center showed a strange look.

"Misdiagnosis?"

"Miracles?"

"It's hard to explain."

As a doctor of medicine at the University of California, Garnett is a top academic expert and a star doctor in the industry, and his research topic is chronic myeloid leukemia.

Pathology is based on the existing documents, and now 80% of them have been sorted out.

Although not able to fully identify, but through the current comb out of the pathology, we can develop related drugs.

Drugs can not cure or alleviate all chronic myeloid leukemia patients, but if they can treat part of them, they can already occupy the first place in the current market and reap more profits.

But now, Garnett looks at the test report in his hand, which is hard to believe.

Now someone has come up with a completely incomprehensible means to treat chronic myeloid leukemia. You know, in terms of R & D achievements, at most, it's just mitigation.

Garnett had already asked the patient about the treatment.

But is it true?

Garnett can't believe it.

Fortunately, the patient once said that he was a partner of Ruihui pharmaceutical. And Garnett and Ruihui pharmaceutical once had a cooperation.

Contact Ruihui pharmaceutical, you can ask for the true news.

Garnett immediately called the head of Ruihui pharmaceutical R & D center.

However, the news, Garnett some dull.

The patient is really a chronic myeloid leukemia patient, and the condition is very serious.

The examination report I just got completely proves that the patient is very healthy now.

It's true.

There is a strong sense of frustration in Garnett's heart, because Garnett has not yet solved the problem.

After feeling frustrated, Garnett remembered that Ruihui pharmaceutical did not have the means to treat chronic myeloid leukemia.

With this in mind, Garnett felt a lot better.

The losers are not just themselves.

"You didn't succeed either." Said Garnett, consciously or unconsciously.

Ruihui pharmaceutical research for at least 20 years, but also did not completely conquer chronic myeloid leukemia.

In the early stage of chronic myeloid leukemia, allogeneic hematopoietic stem cell transplantation is used to cure.

This method can not be regarded as overcoming the disease on the genetic level. It can not be solved in patients with long onset time and disease.

Garnett wants to find a little sense of victory in front of R & D personnel of Ruihui pharmaceutical.

"We've tried a lot. A lot, a lot! "

Emphasizing the diversity of methods can not solve the problem. Even so, it's just an excuse.

"For example?" Garnett is a little funny.

"Ectopic directed inhibition, no success. The partial location method is not successful. And... "

Garnett stayed for a while. Ectopic targeted inhibition is the method he is developing.

It's also the secret technology that he wants to gain great fame.